TriSalus Life Sciences

TriSalus Life Sciences is an oncology company that combines novel delivery technologies with immunotherapy to transform the treatment of patients with liver and pancreatic tumors. The company’s platform includes devices that utilize proprietary drug delivery technology and clinical-stage investigational immunotherapies. The company’s two FDA-approved devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) method to administer a range of treatments: the TriNav® Infusion System for hepatic artery infusion in liver tumors, and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomical limitations of pancreatic arterial infusion. The PEDD method modulates pressure and flow in a way that delivers more treatment to the tumor while aiming to minimize undesired delivery to normal tissues, potentially improving patient outcomes. SD-101 is the company’s investigational immunotherapy candidate, designed to improve patient outcomes by targeting the immunosuppressive environment created by many tumors, which can render current immunotherapies ineffective in the liver and pancreas.